Response to Rogers et al
- PMID: 24217013
- PMCID: PMC3961491
- DOI: 10.1038/jid.2013.450
Response to Rogers et al
Conflict of interest statement
Conflict of interest: Dr. Mary-Margaret Chren is a consultant for Genentech, Inc.
Comment on
-
Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.J Invest Dermatol. 2013 May;133(5):1188-96. doi: 10.1038/jid.2012.403. Epub 2012 Nov 29. J Invest Dermatol. 2013. PMID: 23190903 Free PMC article.
-
Properly selected skin cancer treatments are very effective.J Invest Dermatol. 2014 Apr;134(4):1133-1135. doi: 10.1038/jid.2013.449. Epub 2013 Nov 12. J Invest Dermatol. 2014. PMID: 24217010 No abstract available.
References
-
- Chren MM, Sahay AP, Bertenthal DS, et al. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127:1351–7. - PubMed
-
- Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. Journal of the American Academy of Dermatology. 2012;67:531–50. - PubMed
-
- Elston D. [Accessed September 30 2013];Dermatology is under siege. 2013 < http://www.aad.org/members/aadaadvocacy/dermatology-is-under-siege>.
-
- Essers BA, Dirksen CD, Nieman FH, et al. Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol. 2006;142:187–94. - PubMed
-
- Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical